Prophylactic or therapeutic use of azole anti-fungals is common in CLL/SLL [23], and the agents in this therapeutic class (e.g., voriconazole, posaconazole) are moderate-to-strong inhibitors of CYP3A [24, 25]. Here, CYP3A4 is linked to B-cell chronic lymphocytic leukemia.